DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess of $100,000 From Investment In NewLink Genetics Corporation To Contact The Firm

STEVENSON, Md.--()--The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of NewLink Genetics Corporation (Nasdaq: NLNK) (“NewLink” or the “Company”) securities during the period between September 17, 2013 and May 9, 2016, inclusive (the “Class Period”). Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until July 11, 2016 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in NewLink securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that algenpantucel-L, the Company’s pancreatic cancer treatment, was ineffective and potentially harmful to patients.

According to the complaint, following the May 9, 2016 Company announcement that algenpantucel-L did not meet the main goal in the Company’s Phase 3 IMPRESS study and patients treated with algenpantucel-L lived for a median of 27.3 months compared to a median survival of 30.4 months for patients treated with standard therapy, suggesting that patients were actually harmed by algenpantucel-L, the value of NewLink shares declined significantly.

If you have suffered a loss from investment in NewLink securities purchased on or after September 17, 2013 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

Contacts

Brower Piven, A Professional Corporation
Charles J. Piven, 410-415-6616
1925 Old Valley Road
Stevenson, Maryland 21153
hoffman@browerpiven.com

Contacts

Brower Piven, A Professional Corporation
Charles J. Piven, 410-415-6616
1925 Old Valley Road
Stevenson, Maryland 21153
hoffman@browerpiven.com